



Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ARGS


Last Trade:	0.46
Trade Time:	4:00 PM ET May 26, 2017
Change:	0.05 (+13.389%)
Day Range	0.41 - 0.56
52-Week Range	0.31 - 9.22
Volume	3,451,162

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 10, 2017*
[Argos Provides Update on its ADAPT Trial Following Meeting with FDA](#)
- Apr 18, 2017*
[Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial](#)
- Feb 22, 2017*
[Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review](#)
- Feb 13, 2017*
[Argos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium](#)
- Feb 6, 2017*
[Argos Therapeutics to Participate in BIO CEO and Investor Conference](#)

Financials [\[View all \]](#)

- Mar 16, 2017*
[Annual Report \(10-K\)](#)
- Apr 29, 2016*
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 14, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 15, 2016*
[Quarterly Report \(10-Q\)](#)